EcoR1 Capital, LLC: CRISPR THERAPEUTICS AG (CRSP): Quarterly 13F Position History
As of Q1 2026, EcoR1 Capital, LLC reported 1,389,276 shares of CRISPR THERAPEUTICS AG (CRSP), worth $66.1M and representing 2.8% of its 13F equity book. The position first appeared in Q3 2018 and has been disclosed across 31 13F-HR filings in Pactolio's tracked window.
- 1,389,276Shares Held (Latest Filing)
- $66.1MReported Market Value (Latest Filing)
- 2.8%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$6.8MQuarter-over-Quarter Value Change
- 1,878,277Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 31 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,389,276 | 0 | — | $66.1M | 2.8% | $47.6 |
| Q4 2025 | 1,389,276 | 0 | — | $72.9M | 3.3% | $52.4 |
| Q3 2025 | 1,389,276 | 0 | — | $90.0M | 4.3% | $64.8 |
| Q2 2025 | 1,389,276 | 0 | — | $67.6M | 4.0% | $48.6 |
| Q1 2025 | 1,389,276 | 0 | — | $47.3M | 2.8% | $34.0 |
| Q4 2024 | 1,389,276 | 0 | — | $54.7M | 2.2% | $39.4 |
| Q3 2024 | 1,389,276 | 0 | — | $65.3M | 2.2% | $47.0 |
| Q2 2024 | 1,389,276 | 0 | — | $75.0M | 2.3% | $54.0 |
| Q1 2024 | 1,389,276 | +1,389,276 | — | $94.7M | 2.4% | $68.2 |
| Q4 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2022 | 0 | 1,077,483 | -100.0% | $0 | 0.0% | — |
| Q4 2021 | 1,077,483 | +1,077,483 | — | $81.7M | 2.6% | $75.8 |
| Q3 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2020 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2020 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2020 | 0 | 30,510 | -100.0% | $0 | 0.0% | — |
| Q1 2020 | 30,510 | +30,510 | — | $1.3M | 0.1% | $42.4 |
| Q4 2019 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2019 | 0 | 1,610,250 | -100.0% | $0 | 0.0% | — |
| Q2 2019 | 1,610,250 | 268,027 | -14.3% | $75.8M | 7.8% | $47.1 |
| Q1 2019 | 1,878,277 | +1,669,427 | +799.3% | $67.1M | 7.3% | $35.7 |
| Q4 2018 | 208,850 | 291,150 | -58.2% | $6.0M | 0.7% | $28.6 |
| Q3 2018 | 500,000 | — | — | $22.2M | 2.3% | $44.4 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did EcoR1 Capital, LLC first disclose a CRSP position in 13F-HR filings?
EcoR1 Capital, LLC first reported CRISPR THERAPEUTICS AG (CRSP) on its 13F-HR filing for the period ending 2018-09-30 (Q3 2018). The position has appeared on 31 reported quarters within Pactolio's tracked window.
What was EcoR1 Capital, LLC's most recent quarter-over-quarter share-count change in CRSP?
EcoR1 Capital, LLC held the same 1,389,276 shares of CRSP between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent EcoR1 Capital, LLC's cost basis in CRSP?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.